Abiopharma

🔍 Nakayama Ichiro (Executive)

Company: PayPay Corp (PAYP)

Report Date: 2026-06-09

Detailed Transactions and Holdings:

• Acquired 2,600 shares of Common Shares at $8.11 per share (Direct)
  Date: 2026-06-09 | Code: M | equity_swap_involved: false | shares_owned_after: 57,078.40 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 2,600 shares of Stock Options (Right to Buy) at $8.11 per share (Derivative)
  Date: 2026-06-09 | Code: M | Expires: 2033-03-31 | equity_swap_involved: false | shares_owned_after: 190.00 | transaction_form_type: 4 | Footnotes: F2, F3, F1, F4, F3

Footnotes:

• F1: The Common Shares are represented by American Depositary Shares (ADS). The Common Shares received upon exercise of any Stock Options will be converted into ADSs on a one-for-one basis.
• F2: The exercise price is denominated in Japanese Yen. For purposes of calculating the dollar denominated exercise price per Common Share, the exercise price of JPY 1,300 perCommon Share has been converted to U.S. Dollars at the exchange rate of JPY 160.2600 = US$1.00, which was the foreign exchange rate on June 5, 2026, as reported by theU.S. Federal Reserve in its weekly release on June 8, 2026. The exercise price is the actual Japanese Yen amount regardless of the exchange rate on the date of exercise.
• F3: 190 options to vest in two equal annual installments on April 1, 2027, and April 1, 2028. The Form 3 filed on March 18, 2026, reflected the vesting terms relating to the number of shares underlying such options, with each option exercisable for 200 Common Shares.
• F4: Reflects awards of stock options, with each option exercisable for 200 Common Shares.
• REMARKS: Title: President, Representative Director, CEO and Corporate Officer